Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study
出版年份 2016 全文链接
标题
Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study
作者
关键词
-
出版物
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 43, Issue 10, Pages 1090-1102
出版商
Wiley
发表日期
2016-04-03
DOI
10.1111/apt.13594
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The Expenditures for Academic Inpatient Care of Inflammatory Bowel Disease Patients Are Almost Double Compared with Average Academic Gastroenterology and Hepatology Cases and Not Fully Recovered by Diagnosis-Related Group (DRG) Proceeds
- (2016) Daniel C. Baumgart et al. PLoS One
- Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease
- (2015) P. Luthra et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Pseudomonas Meningitis During Vedolizumab Therapy for Crohn’s Disease
- (2015) Brigid S. Boland et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Tu1368 Vedolizumab in Inflammatory Bowel Disease, the First Experience From the Swedish IBD Registry (SWIBREG)
- (2015) Carl Eriksson et al. GASTROENTEROLOGY
- Tu1369 Vedolizumab Efficacy and Safety in a Tertiary Care IBD Clinical Practice
- (2015) Emily Vivio et al. GASTROENTEROLOGY
- Vedolizumab for Induction and Maintenance of Remission in Ulcerative Colitis
- (2015) Mahmoud H. Mosli et al. INFLAMMATORY BOWEL DISEASES
- Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients
- (2015) Edward Shelton et al. INFLAMMATORY BOWEL DISEASES
- Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
- (2014) Bruce E. Sands et al. GASTROENTEROLOGY
- Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results
- (2014) Tim Wyant et al. GUT
- Smoking in inflammatory bowel disease: Impact on disease course and insights into the aetiology of its effect
- (2014) Gareth C. Parkes et al. Journal of Crohns & Colitis
- Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
- (2014) Séverine Vermeire et al. LANCET
- Comparative Efficacy of Biologic Therapy in Biologic-Naïve Patients With Crohn Disease: A Systematic Review and Network Meta-analysis
- (2014) Siddharth Singh et al. MAYO CLINIC PROCEEDINGS
- Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment
- (2013) Cornelia Tillack et al. GUT
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Review article: ulcerative colitis, smoking and nicotine therapy
- (2012) P. C. Lunney et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population
- (2012) Christina Ha et al. Clinical Gastroenterology and Hepatology
- Ulcerative colitis
- (2012) Ingrid Ordás et al. LANCET
- Crohn's disease
- (2012) Daniel C Baumgart et al. LANCET
- The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study
- (2011) S. Vermeire et al. GUT
- Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: Experience from a consecutive cohort of inflammatory bowel disease patients
- (2011) Daniel C. Baumgart et al. INFLAMMATORY BOWEL DISEASES
- Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis
- (2011) Saskia Thomas et al. INFLAMMOPHARMACOLOGY
- Correlation Between the Crohn's Disease Activity and Harvey–Bradshaw Indices in Assessing Crohn's Disease Severity
- (2010) Severine Vermeire et al. Clinical Gastroenterology and Hepatology
- The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti- 4 7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
- (2009) D. Soler et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis
- (2008) James D. Lewis et al. INFLAMMATORY BOWEL DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started